Stocktoria
Corvus Pharmaceuticals, Inc. CRVS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-03-23
Chart by TradingView
2/9
Piotroski F — financial health
-11.97
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$43.0M | -$27.5M | -$23.4M | -$32.6M | -$38.6M |
| Net income | -$15.3M | -$62.3M | -$27.0M | -$41.3M | -$43.2M |
| Operating cash flow | -$32.8M | -$25.4M | -$23.9M | -$27.0M | -$36.7M |
| Free cash flow | -$33.0M | — | -$24.0M | -$27.3M | -$36.7M |
| Total assets | $71.1M | $68.9M | $45.6M | $68.2M | $109.5M |
| Total liabilities | $9.9M | $36.3M | $6.9M | $12.1M | $12.3M |
| Shareholders' equity | $61.2M | $32.6M | $38.7M | $56.1M | $97.2M |
| Ratios | |||||
| Return on assets | -21.5% | -90.4% | -59.3% | -60.5% | -39.5% |
| Return on equity | -25.0% | -191.3% | -69.9% | -73.6% | -44.5% |
| Current ratio | 6.21 | 1.54 | 4.07 | 4.06 | 7.36 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 81,310 | $1.2M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -11.97 (distress)
- Working capital / assets 0.687
- Retained earnings / assets -5.797
- EBIT / assets -0.604
- Equity / liabilities 6.174
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001626971 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.